While chronic myelomonocytic leukemia (CMML) is a rare disease, it is not rare to the patients and loved ones who are affected by it.

In this episode, Dr. Mrinal Patnaik of the Mayo Clinic in Rochester, MN, discusses the unique aspects of CMML and how it is classified and treated.  Dr. Patnaik shares the latest treatment advances and discusses the importance of patients’ quality of life.

Podcast: Play in new window | Download

Subscribe: Google Podcasts | Spotify | Pandora | Blubrry | JioSaavn | Podchaser | More

CLICK HERE to participate in our episode survey.

Mentioned on this episode: 

• Chronic myelomonocytic leukemia (CMML)
• Myeloproliferative Neoplasms (MPNs)
• Myelodysplastic syndromes (MDS)
• Acute myeloid leukemia (AML)
• Stem Cell Transplantion
• Graft-vs-host Disease (GVHD)
• Minimal/Measurable Residual Disease (MRD)
• Clinical Trial Support Center
• Spanish Risk Stratification System
• French Risk Stratification System
• RAS mutations (study) – Nature Communications
•  TET2 mutations (study) – Leukemia
• Decitabine Versus Hydroxyurea (study)– Journal of Clinical Oncology

Additional LLS Support Resources: 

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Financial support
• Caregiver support 
• Young Adult Resources
• Survivorship Workbook
• Online chats 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program 
• Free Nutrition Consultations

Support for this episode provided by: Taiho Oncology, Inc.